PubMed · 1989 · 37 citations · 0 references
Human Hepatocellular CarcinomaImmunologyPathologyCancer BiologyTumor BiologyMyc OncogenesCancer Cell BiologyNon-neoplastic Liver TissuesRadiation OncologyHuman HccCancer ResearchHealth SciencesOncogenic AgentLiver PhysiologyHistopathologyRas P21 ExpressionHepatologyHepatitisLiver DiseaseLiver CancerLiverMedicineHepatocellular CarcinomaRas P21
An immunohistochemical assay was used to assess expression of ras p21 and myc p62 oncogene products in human hepatocellular carcinoma (HCC) and non-neoplastic liver tissues. The monoclonal antibodies Y13 259 and Myc1-9E10, specific for ras p21 and myc p62 oncoproteins, were employed on paraffin-embedded sections. Most HCCs showed enhanced ras p21 and myc p62 expression, as indicated by staining intensity. Cirrhotic livers revealed increased myc p62 and occasionally increased ras p21 expression. HBsAg+ hepatocytes showed intense immunostaining for ras p21. Fibrotic, cholestatic, fetal and normal adult liver did not present enhancement of oncoprotein production. We suggest that combined over-expression of ras and myc oncoproteins may be important for the malignant phenotypic alteration in human HCC.